Lamivudine/raltegravir

Lamivudine/raltegravir
Combination of
Lamivudine	Reverse-transcriptase inhibitor
Raltegravir	Integrase inhibitor
Clinical data
Trade names	Dutrebis
Routes of; administration	Oral
ATC code	J05AR16 (WHO) ;
Legal status
Legal status	US: ℞-only;
Identifiers
CAS Number	2446160-46-7;
KEGG	D10754;

Lamivudine/raltegravir, sold under the brand name Dutrebis, is a fixed-dose combination antiretroviral medication used in the treatment of HIV/AIDS.^[1] It contains lamivudine and raltegravir. It is taken by mouth.^[1] Side effects may include lactic acidosis, pancreatitis, liver failure, and severe skin rashes.^[1] It was approved for medical use in the United States in 2015.^[1]^[2]

Quick facts Combination of, Raltegravir ...

Lamivudine/raltegravir is not available in the United States.^[3]

References